MedTrace Logo

Thalidomide in Treating Patients With Gynecologic Sarcomas

NCT00006005 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent gynecologic sarcomas.

Conditions

Interventions

DRUG

thalidomide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • New York University Cancer Institute

    lead OTHER

Principal Investigators

  • Scott Wadler, MD · Weill Medical College of Cornell University

Study Design

Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006005 on ClinicalTrials.gov